I think that Rob Davis at Merck, that's been a one-way stock. Down. Even though he's done some terrific things. He's got a great heart drug. But it doesn't seem to matter at all." Overall MRK ...

In an interview on CNBC’s Mad Money, Robert Davis said Merck’s (MRK) current pipeline is the most diversified it has been in recent history. “We’re not just a Keytruda company, we’re an ...

In a leafy New Jersey suburb, police began regularly checking the home of Robert Davis, CEO of pharmaceutical giant Merck on Dec. 8, according to emergency dispatch records. Officers continued ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...

Merck CEO Rob Davis stated they have 20 potential new pipeline treatment growth drivers, almost all of which have blockbuster ...

Merck CEO Rob Davis said that the company’s outlook for after 2028 is far better than it was in 2021, when he arrived in his current role. “If we can continue to make the same kind of progress ...

CEO Rob Davis said during Merck’s fourth quarter earnings call. Merck shares fell by as much as 12% in morning trading as investors reassessed their outlook on the company’s second-biggest ...

Merck is seeking to reassure investors when ... At an investor conference in January, CEO Rob Davis said the company is “seeing the situation stabilizing in the marketplace out there.” ...